DoseGear research brief
Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87. 5% improvement in knee pain patients per Lee & Padgett 2021 study.
DG Peptide Protocols
Well StudiedHealing & RecoveryLongevity
Wolverine Stack
BPC-157/TB-500 combination
BPC-157 + TB-500 | Tissue Repair & Recovery Protocol
Research overview
Mechanism of action
BPC-157 increases actin production and modulates nitric oxide for vascular effects; TB-500 sequesters actin for cell migration; synergistic enhancement of fibroblast and immune cell movement to injury sites.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Marketed BPC-157 and TB-500 combination; a specific developer is not established.
What it is researched for
Proposed injury-repair applications based on complementary ingredient mechanisms; clinical synergy is unestablished.
Research observation window
Not reported for the combination.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| General Recovery Protocol | BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week | BPC-157 daily, TB-500 twice weekly | SubQ |
| Intensive Injury Recovery | BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week | BPC-157 daily, TB-500 twice weekly | SubQ near injury site |
| Maintenance/Prevention Protocol | BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week | BPC-157 daily, TB-500 weekly | SubQ |
Reference cycle
4-8 weeks for injury recovery; shorter for maintenance
Reference storage
Lyophilized powder: room temperature acceptable; Reconstituted: 2-8°C refrigerated for both peptides
Safety context
Reported side effects
- Not extensively documented in human studies
- Generally well-tolerated in available research
Contraindications & cautions
- ANY history of cancer or suspicious growths
- Active malignancy or concurrent chemotherapy
- Pregnancy or breastfeeding
Scientific references
- 01
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Scientific citationIntra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine (2021). - 02
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Scientific citationEmerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal (2025). - 03
The Regenerative Peptide Thymosin Beta-4 Accelerates the Rate of Dermal Healing in Preclinical Animal Models and in Patients
Scientific citationThe Regenerative Peptide Thymosin Beta-4 Accelerates the Rate of Dermal Healing in Preclinical Animal Models and in Patients. Annals of the New York Academy of Sciences (2012). - 04
Thymosin Beta-4: A Multi-Functional Regenerative Peptide. Basic Properties and Clinical Applications
Scientific citationThymosin Beta-4: A Multi-Functional Regenerative Peptide. Basic Properties and Clinical Applications. Expert Opinion on Biological Therapy (2012).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.